TORONTO and HOUSTON — February 18, 2026 — Leads & Copy — Medicenna Therapeutics Corp., a clinical-stage immunotherapy company (TSX: MDNA, OTCQX: MDNAF), announced its participation in several upcoming conferences. The company focuses on developing Superkines for cancer, autoimmune, and inflammatory diseases.
These events will allow Medicenna to showcase its latest developments and engage with the industry and investment community.
Medicenna will participate in the following conferences:
The 7th Annual Glioblastoma Summit: Trailblazing Next-Generation Glioblastoma & Glioma Therapies will take place on February 19th, 2026, in Boston, MA. Dr. Fahar Merchant will present on “Surmounting Barriers in Non-resectable Recurrent Glioblastoma with a Single Treatment of Bizaxofusp, an Engineered IL-4R Directed Fusion Protein” at 10:00 AM EST. The summit will feature presentations and panel discussions.
The BIO Investment and Growth Summit will be held March 2-3, 2026, in Miami, FL. The company will participate in one-on-one meetings.
The 38th Annual ROTH Conference will take place March 22-24, 2026, in Dana Point, CA. Medicenna will participate in a fireside chat and one-on-one meetings. A webcast will be available at https://ir.medicenna.com/news-and-events/events-and-presentations.
The BIO-Europe Spring Conference will be held March 23-25, 2026, in Lisbon, Portugal. The company will participate in one-on-one meetings.
Medicenna is focused on developing novel versions of IL-2, IL-4, and IL-13 Superkines and first-in-class Empowered Superkines. The company’s long-acting IL-2 Superkine, MDNA11, preferentially stimulates cancer-killing effector T cells and NK cells. Medicenna’s targeted PD-1 x IL-2 bispecific, MDNA113, is in development for solid tumors using the company’s BiSKITs™ and T-MASK™ platforms.
Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials involving over 130 patients. This includes a Phase 2b trial for recurrent GBM, a fatal form of brain cancer. Bizaxofusp has received FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.
Source: Medicenna Therapeutics
